AREDIA
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AREDIA (pamidronate disodium) is an injectable bisphosphonate approved in 1991 for treating hypercalcemia of malignancy and osteolytic bone metastases. It works by inhibiting osteoclast-mediated bone resorption, reducing calcium release into the bloodstream and slowing bone destruction in cancer patients.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), brand team focus is likely on defending market share against generics and optimizing margin rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AREDIA currently has zero linked job openings, reflecting its mature, LOE-approaching lifecycle. Roles on this product emphasize commercial execution and defensive positioning rather than growth or innovation.
Brand ManagerProduct Manager
Worked on AREDIA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.